Top

Osteoporosis International

Published in:

01-07-2016 | Short Communication

Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture

Authors: M. El-Haj, I. Gurt, E. Cohen-Kfir, V. Dixit, H. Artsi, L. Kandel, O. Yakubovsky, O. Safran, R. Dresner-Pollak

Published in: Osteoporosis International | Issue 7/2016

Abstract

Summary

To investigate the role of Sirtuin1 in osteoporosis, Sirtuin1 was determined at the femoral neck in female patients undergoing hip operation for fractured hip or osteoarthritis. Reduced Sirtuin1 was found in osteoporotic patients. Pharmacologic activation of Sirtuin1 reduced sclerostin, an inhibitor of bone formation. Activation of Sirtuin1 may be a new direction to generate therapies for osteoporosis.

Introduction

The aim of the study are to investigate the role of Sirtuin1 (Sirt1), an anti-aging factor and a player in age-associated diseases, in osteoporotic hip fractures, and test the hypothesis that Sirt1 is a negative regulator of sclerostin, a bone formation inhibitor, in human femoral bone marrow mesenchymal cells (BM-MSCs).

Methods

Sirt1 and sclerostin were determined by western blot in bone samples obtained intra-operatively from the inferior medial cortex of the femoral neck (calcar region) in female patients undergoing partial hip replacement for fractured neck of femur (N = 10) or hip replacement for osteoarthritis (N = 8) (mean ± SD age 81 ± 8.1 vs. 68 ± 9.3 years; BMI 26.2 ± 3.6 vs. 25.9 ± 7.1 kg/m² in osteoporotic and osteoarthritis patients). Calcar thickness and femoral bone mineral density (BMD) were determined preoperatively by X-ray using a digital TraumaCad^™ software and DEXA. Femoral BM-MSCs were collected intra-operatively and treated with SRT3025, a Sirt1 activator. Sclerostin and dentin matrix acidic phosphoprotein (DMP1) were determined by western blot and messenger RNA (mRNA) expression of Lef1 and DMP1 was evaluated by quantitative real-time PCR.

Results

Osteoporotic (OP) patients had reduced cortical thickness, femoral neck, and total hip BMD compared to osteoarthritis (OA) patients. Calcar Sirt1 expression was significantly reduced, while sclerostin was markedly increased in OP compared to OA patients. Sirt1 and sclersotin expressions were inversely correlated (r = −0.49, P = 0.047). SRT3025 administration down-regulated sclerostin and up-regulated DMP1 protein level and increased LEF1 and DMP1 mRNA expressions in OP patient-derived BM-MSCs.

Conclusions

Reduced femoral neck Sirt1 may play a role in osteoporotic hip fractures in part via influencing local sclerostin expression. The therapeutic potential of Sirt1 activation in osteoporosis warrants further investigation.

Anderson KA, Green MF, Huynh FK, Wagner GR, Hirschey MD (2014) SnapShot: mammalian sirtuins. Cell 159(4):956–956 e951. doi:10.1016/j.cell.2014.10.045 CrossRefPubMedPubMedCentral

Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D’Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R (2011) Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152(12):4514–4524. doi:10.1210/en.2011-1128 CrossRefPubMed

Iyer S, Han L, Bartell SM, Kim HN, Gubrij I, de Cabo R, O’Brien CA, Manolagas SC, Almeida M (2014) Sirtuin1 (Sirt1) promotes cortical bone formation by preventing beta-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem 289(35):24069–24078. doi:10.1074/jbc.M114.561803 CrossRefPubMedPubMedCentral

Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, Moore MM, Lwin ST, Yull FE, Mundy GR, Elefteriou F (2013) Silent information regulator (Sir)T1 inhibits NF-kappaB signaling to maintain normal skeletal remodeling. J Bone Miner Res Off J Am Soc Bone Miner Res 28(4):960–969. doi:10.1002/jbmr.1824 CrossRef

Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, Baron R, Scadden D, Schipani E, Guarente L (2013) SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating beta-catenin. EMBO Mol Med 5(3):430–440. doi:10.1002/emmm.201201606 CrossRefPubMedPubMedCentral

Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M (2010) Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1:3. doi:10.1038/ncomms1001 CrossRefPubMedPubMedCentral

Baron R, Kneissel M (2013) Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19(2):179–192. doi:10.1038/nm.3074 CrossRefPubMed

Artsi H, Cohen-Kfir E, Gurt I, Shahar R, Bajayo A, Kalish N, Bellido TM, Gabet Y, Dresner-Pollak R (2014) The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology 155(9):3508–3515. doi:10.1210/en.2014-1334 CrossRefPubMed

Zarrabeitia MT, Valero C, Martin-Escudero JC, Olmos JM, Bolado-Carrancio A, de Sande-Nacarino EL, Rodriguez-Rey JC, Sainz J, Riancho JA (2012) Association study of Sirtuin1 polymorphisms with bone mineral density and body mass index. Arch Med Res 43(5):363–368. doi:10.1016/j.arcmed.2012.06.012 CrossRefPubMed

10.

Zhang Q, Chen W, Liu HJ, Li ZY, Song ZH, Pan JS, Zhang YZ (2009) The role of the calcar femorale in stress distribution in the proximal femur. Orthop Surg 1(4):311–316. doi:10.1111/j.1757-7861.2009.00053.x CrossRefPubMed

11.

Lotz JC, Cheal EJ, Hayes WC (1995) Stress distributions within the proximal femur during gait and falls: implications for osteoporotic fracture. Osteoporos Int J Establish Result Cooperation Eur Found Osteoporos Nat Osteoporos Found USA 5(4):252–261CrossRef

12.

Mackay DL, Tesar PJ, Liang LN, Haynesworth SE (2006) Characterizing medullary and human mesenchymal stem cell-derived adipocytes. J Cell Physiol 207(3):722–728. doi:10.1002/jcp.20617 CrossRefPubMed

13.

Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, SY E, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA (2013) Evidence for a common mechanism of Sirt1 regulation by allosteric activators. Science 339(6124):1216–1219. doi:10.1126/science.1231097 CrossRefPubMedPubMedCentral

14.

Dvir-Ginzberg M, Steinmeyer J (2013) Towards elucidating the role of Sirt1 in osteoarthritis. Front Biosci 18:343–355CrossRef

15.

Gagarina V, Gabay O, Dvir-Ginzberg M, Lee EJ, Brady JK, Quon MJ, Hall DJ (2010) SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. Arthritis Rheum 62(5):1383–1392. doi:10.1002/art.27369 CrossRefPubMedPubMedCentral

16.

Jordan GR, Loveridge N, Bell KL, Power J, Dickson GR, Vedi S, Rushton N, Clarke MT, Reeve J (2003) Increased femoral neck cancellous bone and connectivity in coxarthrosis (hip osteoarthritis). Bone 32(1):86–95CrossRefPubMed

17.

Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alias AM, Lowik C, Papapoulos S, Reeve J, Loveridge N (2010) Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res Off J Am Soc Bone Miner Res 25(8):1867–1876. doi:10.1002/jbmr.70 CrossRef

18.

Kilic U, Gok O, Erenberk U, Dundaroz MR, Torun E, Kucukardali Y, Elibol-Can B, Uysal O, Dundar T (2015) A remarkable age-related increase in SIRT1 protein expression against oxidative stress in elderly: SIRT1 gene variants and longevity in human. PLoS One 10(3):e0117954. doi:10.1371/journal.pone.0117954 CrossRefPubMedPubMedCentral

19.

Kumar R, Mohan N, Upadhyay AD, Singh AP, Sahu V, Dwivedi S, Dey AB, Dey S (2014) Identification of serum sirtuins as novel noninvasive protein markers for frailty. Aging cell 13(6):975–980. doi:10.1111/acel.12260 CrossRefPubMedPubMedCentral

Title: Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture
Authors: M. El-Haj
I. Gurt
E. Cohen-Kfir
V. Dixit
H. Artsi
L. Kandel
O. Yakubovsky
O. Safran
R. Dresner-Pollak
Publication date: 01-07-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 7/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3536-4

At a glance: The STEP trials

Springer Medicine

Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2016

Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group

Association of bone mineral density and diabetic retinopathy in diabetic subjects: the 2008–2011 Korea National Health and Nutrition Examination Survey

Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α

Vitamin E homologues α- and γ-tocopherol are not associated with bone turnover markers or bone mineral density in peri-menopausal and post-menopausal women

Continued decline in hip fracture incidence in Norway: a NOREPOS study